ascopubs.org

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial

Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose–Positron Emission Tomography OPTICAL was a randomized, ...
Seeking Alpha

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...
ascopubs.org

Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of ...

Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization We trained, tested, and validated a machine ...
Healio

Neoadjuvant talazoparib induces pathologic complete response in breast cancer subset

Please provide your email address to receive an email when new articles are posted on . Talazoparib (Talzenna, Pfizer), a poly(ADP)-ribose polymerase (PARP) inhibitor, also appeared generally ...
Nasdaq

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 ...

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage ...